Liposomal Amphotericin B (AmBisome) is a medication used to treat serious fungal infections. In this trial, it is specially prepared as a nebulized solution that patients can inhale through a nebulizer. The medication is mixed with a radioactive substance called Technetium-99m, which allows researchers to track exactly where the medicine goes in the lungs. This helps them understand how well the medication spreads throughout the lungs when it’s inhaled, which is particularly important for treating fungal infections in the lungs like aspergillosis.

Technetium-99m is a medical tracer that produces very low levels of radiation. It is commonly used in medical imaging to help doctors see how substances move through the body. In this study, it is attached to the AmBisome medication to make it visible during scanning, allowing researchers to track how the medication distributes in the lungs after inhalation.

Chronic Pulmonary Aspergillosis – A fungal infection that develops in the lungs caused by Aspergillus species, typically occurring over several months or years. The condition involves the gradual development of cavities in the lungs, which may be accompanied by the formation of fungal balls. The infection usually affects people who already have other lung conditions or weakened immune systems. The disease causes the lung tissue to develop scarring over time, and may lead to the thickening of the walls of air spaces within the lungs. Symptoms typically develop gradually and include persistent cough, shortness of breath, and mild fever.